50 related articles for article (PubMed ID: 12917043)
1. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
[TBL] [Abstract][Full Text] [Related]
2. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients.
Maecker B; von Bergwelt-Baildon MS; Anderson KS; Vonderheide RH; Anderson KC; Nadler LM; Schultze JL
Clin Exp Immunol; 2005 Sep; 141(3):558-62. PubMed ID: 16045747
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors.
Choi W; Lee Y; Choi BK; Park BM; Kim YH; Yun T; Lee WJ; Yoo H; Baek JY; Woo SM; Lim MC; Kwon BS
Cytotherapy; 2023 Nov; 25(11):1236-1241. PubMed ID: 37632518
[TBL] [Abstract][Full Text] [Related]
4. Reverse translation: the key to increasing the clinical success of immunotherapy?
Vanmeerbeek I; Naulaerts S; Garg AD
Genes Immun; 2023 Oct; 24(5):217-219. PubMed ID: 37697000
[No Abstract] [Full Text] [Related]
5. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
8. In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer.
Amarnath SM; Dyer CE; Ramesh A; Iwuagwu O; Drew PJ; Greenman J
Int J Oncol; 2004 Jul; 25(1):211-7. PubMed ID: 15202008
[TBL] [Abstract][Full Text] [Related]
9. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
Pang JX
Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
[TBL] [Abstract][Full Text] [Related]
10. Telomerase as a universal tumor-associated antigen for cancer immunotherapy.
Vonderheide RH
Oncogene; 2002 Jan; 21(4):674-9. PubMed ID: 11850795
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy targeting the telomerase reverse transcriptase.
Huo LF; Tang JW; Huang JJ; Huang PT; Huang CF; Kung HF; Lin MC
Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
